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Abstract 
BACKGROUND: To identify a serum prolactin (PRL) cut-off value indicative of a PRL-
producing adenoma in women with Polycystic Ovarian Syndrome (PCOS) and 
hyperprolactinemia and characterize such patients. 
MATERIALS AND METHODS: In the present retrospective case-control study the medical 
records of 528 PCOS women were reviewed. Pituitary magnetic resonance imaging (MRI) 
was performed in PCOS patients with PRL levels ≥94.0 ng/mL and/or symptoms suspicious 
of a pituitary adenoma (PA). Prolactinoma diagnosis was made in the presence of an MRI-
identifiable PA with biochemical and radiological response to dopamine agonists. Receiver 
operating characteristic (ROC) curve analysis was performed to determine a serum PRL 
threshold that could identify hyperprolactinemic PCOS subjects with prolactinomas. 
Clinical, metabolic and endocrine parameters were also analysed.  
RESULTS: Among 528 patients with PCOS, 60 (11.4%) had elevated PRL levels. Of 44 
(73.3%) patients who had pituitary imaging, 19 had PAs, 18 normal MRI and 7 other 
abnormalities. Patients harboring prolactinomas had significantly higher PRL levels 
compared to patients without adenomas (median PRL 95.4 vs. 49.2 ng/mL, p<0.0001). A 
PRL threshold of 85.2 ng/mL could distinguish patients with prolactinomas with 77% 
sensitivity and 100% specificity [Area Under the curve (AUC) (95%) 0.91(0.8-1.018), 
p=0.0001]. PCOS women with prolactinomas were younger and had lower LH levels 
compared to women without prolactinomas.  
CONCLUSIONS: In women with PCOS, PRL levels exceeding 85.2 ng/mL are highly 
suggestive of a prolactinoma  warranting pituitary imaging. Pituitary MRI could also be 
considered in young PCOS patients with milder PRL elevation and low LH levels.  
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Introduction 
Polycystic ovary syndrome (PCOS) is the commonest endocrinopathy in women of 
reproductive age with a prevalence of 6-10% (1-3). Chronic oligo-anovulation and 
hyperandrogenism constitute the cardinal features of PCOS, while insulin resistance and 
hyperinsulinemia contribute substantially to its pathogenesis, clinical/biochemical 
manifestations and long-term sequelae (4). Current guidelines endorse the use of the 
Rotterdam criteria for diagnosing PCOS (5). 
 
Elevated prolactin (PRL) levels have been reported with a prevalence ranging between 7-
52% in PCOS attributed to the abnormal hormonal milieu as well as a relative dopamine 
deficiency (6-11). Hyperprolactinemia is also common in women of  reproductive age (12), 
and may mimic the clinical phenotype of PCOS (6, 13, 14). Prolactinomas are the most 
frequent cause of non-puerperal endogenous hyperprolactinemia, accounting for 40% of 
all pituitary adenomas (14). Although PRL levels >250 ng/mL are highly indicative of a 
prolactinoma, a significant number of patients with mild to moderate elevations of PRL 
may still harbour a prolactinoma after excluding other causes of hypeprolactinemia (13, 
14). This is particularly relevant in patients with PCOS and concomitant 
hyperprolactinemia as pathophysiology and their treatment may be different compared to 
normoprolactinemic PCOS (10, 15, 16).  Magnetic resonance imaging (MRI) is the modality 
of choice for diagnosising pituitary adenomas, especially microadenomas (13). However, it 
has not been substantiated whether  hypeprolactinemic PCOS patients should undergo 
pituitary MRI to exclude a prolactinoma based on serum PRL concentrations. This is of 
relevance as the presence of a pituitary microadenoma on pituitary MRI in PCOS patients 
with moderately elevated PRL concentrations may well represent an incidentaloma.  
There is currently a paucity of data on the association between PCOS and prolactinomas 
(10, 17). In addition, since there is no clear cut-off value of serum PRL level that could be 
used to distinguish between functional hyperprolactinemia and the presence of a 
prolactinoma in PCOS, the criteria for further evaluation of such patients with pituitary 
imaging rely largely upon each clinician’s threshold. 
The aim of the present retrospective case-control study was the identification of a serum 
PRL cut-off value above which a pituitary MRI could be justifiable in hyperprolactinemic 
PCOS patients. We also aimed to identify clinical, metabolic and endocrine features of 
patients with PCOS and microprolactinomas and compare them to those of patients with 
PCOS and hyperprolactinemia without adenoma and normoprolactinemic PCOS subjects.  
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Materials and Methods  
We retrospectively reviewed the records of 620 patients who attended the General 
Endocrine and PCOS Outpatient clinics at WISDEM Centre (Warwickshire Institute for the 
Study of Diabetes, Endocrinology and Metabolism) and Centre for Reproductive Medicine 
(CRM), University Hospitals Coventry and Warwickshire NHS Trust (UHCW) for menstrual 
disorders, infertility or hirsutism between 2002 and 2016. The study was approved by the 
UHCW audit Department.  
 
Out of 620 patients, 528 met at least two out of the three Rotterdam criteria for the 
diagnosis of PCOS, in the absence of other conditions with PCOS-like phenotype (5, 18). 
Patients without serum PRL measurement  were excluded (Figure 1).  
 
Hyperprolactinemia, defined as PRL levels greater than the upper limit of normal (14) 
(UNL >23.6 ng/mL) in at least two different samples collected on two different days, was 
found in 76 patients (14.4%). Of these 76 patients 16 were excluded as 
hyperprolactinemia was attributed to another pathology (12 patients were receiving 
medications known to affect PRL levels, 2 were pregnant, and 1 had stress-related 
hyperprolactinemia. Screening for macroprolactin was performed in 19 patients with 
hyperprolactinemia and normal menstrual cycles and was positive in one. After exclusion 
of these 16 patients, 60 women were included in the hyperprolactinemic PCOS group of 
our study.   
 
Further assessment with pituitary MRI was performed in patients with PRL levels ≥94.0 
ng/mL (14), and in those with mild-to moderate persistent hyperprolactinemia and 
concomitant symptoms that could be attributed to a pituitary adenoma such as 
unaccounted headaches, prolonged amenorrhea and/or galactorrhea. 
 
The diagnosis of prolactinoma was made in patients with hyperprolactinemia who had an 
MRI-identifiable pituitary adenoma that responded to treatment with dopamine agonists 
(DAs) with normalization of PRL levels and substantial reduction in the size or resolution 
of the adenoma on follow-up MRI scans (13, 14). 
 
Only patients with microprolactinomas (measuring less than 10 mm) were included in our 
analysis. Subjects with adenomas who showed no response to treatment with DAs or 
other MRI abnormalities were excluded. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Clinical parameters: Data collected included: age, body mass index (BMI=Kg/m2), the 
presence of hirsutism/acne, galactorrhoea, and menstrual history. Oligomenorrhea was 
defined as cycles occurring at intervals greater than 35 days or less than 8 menstrual 
cycles per year. Amenorrhea was defined as the absence of menstrual cycles for more 
than 6 months (19). 
 
Biochemical parameters: Fasting blood samples were obtained in the morning during early 
follicular phase in patients with regular menstrual cycles, 2 days after a 7-day 
progesterone-only pill course in patients with oligomenorrhea or randomly in patients 
with amenorrhea.  
The following parameters were recorded: serum concentrations of cholesterol, glycated 
hemoglobin A1c (HbA1c), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), 
follicle-stimulating hormone (FSH), PRL, Testosterone, dehydroepiandrosterone sulfate 
(DHEA-S), estradiol (E2), sex hormone-binding globulin (SHBG). Free-androgen index (FAI) 
was calculated as follows: total testosterone (nmol/L) x 100/SHBG (nmol/L).  
 
Assays: PRL was measured using Prolactin II on Roche cobas e 602, which is a sandwich 
electrochemiluminescence immunoassay.  The manufacturer states the assay has the 
following precision: 1.8% at 13.6 ng/mL, 1.4% at 41.1 ng/mL and 1.6% at 211.2 ng/mL.  
The laboratory has also established its own precision data: 1.97% at 2.0 ng/mL, 1.94% at 
36.5 ng/mL and 1.59% at 83.2 ng/mL. 
Other measurements: Assays were performed using an automated analyzer (Abbott 
Architect; Abbott Laboratories, Abbott Park, IL). 
  
Imaging studies: Gadolinium-enhanced MRI scans of the pituitary were performed at the 
radiology department and were reviewed by the same radiologist (HM). 
 
Firstly, we aimed to identify a threshold for serum PRL that could distinguish 
hyperprolactinemic PCOS patients with microprolactinomas from those without. We also 
compared the clinical, metabolic and endocrine parameters of patients with PCOS and 
microprolactinomas (Group A) to those of patients with PCOS, hyperprolactinemia and 
normal MRI findings (Group B) and age- and BMI-matched PCOS patients with normal PRL 
levels (Group C).  
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Statistical Analysis  
 
Comparisons of categorical variables between groups were performed using the Fisher's 
exact test. The non-parametric Mann-Whitney U test was used to compare not normally 
distributed continuous variables between two groups. Comparisons between three groups 
were assessed using the one-way ANOVA and Kruskal–Wallis tests, for normally and not-
normally distributed variables respectively.  The results were presented as a) mean±SD or 
median (range) for continuous variables with or without normal distribution, respectively 
b) frequency for categorical variables. Statistical analyses were performed using the 
statistical package PRISM 7. P-values <0.05 were considered as statistically significant. 
Receiver operating characteristic (ROC) curve analysis was performed in order to 
determine the cut-off value for serum PRL levels. 
 
Results 
Out of 60 patients with PCOS and concomitant hyperprolactinemia, 44 (73.3%) underwent 
MRI of the pituitary: 8/44 patients had serum PRL levels  ≥94.0 ng/mL (range: 94.0-351.5 
ng/mL) and 36/44 had mild-moderate hyperprolactinemia (PRL range: 25.3-93.7 ng/mL) 
and  symptoms suspicious of a pituitary adenoma as previously defined. Four patients had 
minimal PRL elevations (25.3-31.1 ng/mL) and were imaged due to persistent headache 
and prolonged amenorrhea.  
 
Of the remaining 16 patients, 14 displayed mild increases in their serum PRL levels (range: 
23.8-35.4 ng/mL) in the absence of associated symptoms. A further 2 patients were 
claustrophobic and were unable to undergo MRI (PRL levels 47.3 and 51.0 ng/mL, 
respectively). 
 
Of the 44 hyperprolactinemic PCOS patients who had pituitary imaging, 19 patients had 
pituitary adenomas, 18 had normal MRI findings and 7 other abnormalities (1 Rathke’s 
cyst, 1 duplication and thickening of the pituitary stalk, 1 diffusely enlarged pituitary 
gland, 4 mild asymmetry of the pituitary gland with homogeneous or slightly 
inhomogeneous enhancement but no focal mass indentified). Median PRL levels in this 
latter group were 47.3 ng/mL (range: 39.3-75.3). 
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Among 19 patients with pituitary adenomas, 17 had microadenomas and 2 
macroadenomas. The latter were initially referred for persistent headache, secondary 
amenorrhea and galactorrhea and were found to have non-functioning pituitary 
adenomas (NFPA) along with PCOS  (PRL: 30.3 and 94.0 ng/mL) and were excluded from 
the analysis. 
Out of 17 patients with microadenomas, 2 did not receive treatment with DAs (PRL: 71.1 
and 74.7 ng/mL) and 2 showed no radiological response to treatment with DAs, i.e no 
reduction in tumour size on follow-up MRI scans besides normalization of their PRL levels 
(baseline PRL: 74.2 and 49.0 ng/mL). Thus, the diagnosis of a microprolactinoma could not 
be established based on the previously mentioned criteria and  were excluded from 
analysis. 
 
The remaining 13 women consisted Group A of our study, i.e PCOS patients with elevated 
PRL levels due to concomitant microprolactinomas (Figure 1). Median PRL levels in this 
patient group were  95.4 ng/mL (range: 48.3-351.5) (Table 2). Following initiation of 
treatment with DAs, all these patients with a provisional diagnosis of a prolactinoma 
obtained normalization/substantial reduction of their PRL levels along with a significant 
tumour reduction (n=9/13, 69.2%, median reduction: 47.2%, range: 25-100%) or resolution 
(n=4/13) of the previously noted pituitary adenoma. 
Group B of our study consisted of 18 hyperprolactinemic PCOS subjects who had normal 
pituitary MRI (Figure 1). Median PRL levels in this patient group were 49.2 ng/mL (range: 
25.3-84.3) (Table 2). 
 
A further 30 age- and BMI-matched patients with PCOS and normal PRL levels (Group C) 
formed our control group.  
 
A. Distribution of PRL levels in patients with PCOS and hyperprolactinemia and PRL 
thresholds as predictors of prolactinomas 
 
Pituitary adenomas were identified in: 33.3% of patients with PRL levels ranging between 
47.2-70.8 ng/mL (2/6), 44.4% with PRL levels between 70.8-94.0 ng/mL (4/9) and 100% 
with PRL levels ≥94.0 ng/mL (7/7). None of the patients with PRL values less than 47.2 
ng/mL had an identifiable adenoma on MRI scan.  
 
Patients harboring prolactinomas had significantly higher PRL  levels compared to patients 
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with no adenomas  (P<0.0001) (Table 2). Following initiation of treatment with DAs 
patients with prolactinomas responded with normalization or substantial decrease in 
serum PRL levels (median PRL post-treatment: 14.7 ng/mL, range: 1.2-26.4) and  
significant reduction in the size of adenoma on follow-up MRI scans (median pituitary 
adenoma size, pre- vs post-treatment: 7.7 vs 2.5 mm, P=0.005) (Table 1).  
 
ROC curve analysis was performed in order to determine a cut-off value of serum PRL that 
could identify hyperprolactinemic PCOS subjects with adenomas. The Area Under the 
curve (AUC) value was 0.91, indicating a high accuracy. Several PRL cut-off values were 
analyzed in order to obtain acceptable sensitivity and specificity. A cut-off PRL value of 
47.5 ng/mL could correctly identify all patients with prolactinomas, albeit with a low 
specificity (50%), as 9 out of 18 patients with no identifiable adenoma had PRL levels 
higher than 47.5 ng/mL [positive and negative predictive value (PPV) of 59.1% and (NPV) 
of 100% respectively]. A PRL threshold of 85.2 ng/mL could distinguish patients with 
prolactinomas with a sensitivity of 77% and a high specificity of 100% [AUC 
(95%)=0.91(0.8-1.018), P=0.0001] (PPV and NPV were 100% and 85.7%, respectively, 
diagnostic accuracy: 90.3%) [Figure 2(Α) and (Β)]. 
 
B. Comparisons between Groups A, B and C  
Clinical, metabolic and endocrine features of patients in Groups A, B and C are shown in 
Tables 1 and 2. 
 
1. Clinical parameters 
Women in Group A were younger compared to women in Group B (P=0.03) (Table 1). No 
differences were observed in the frequency of clinical hyperandrogenism, menstrual 
irregularities or PCO morphology between the three groups and BMI or the frequency of 
galactorrhea between groups A and B.  
 
B. Metabolic and endocrine parameters 
Serum PRL levels (pre-treatment) were significantly higher in Group A compared to Group 
B (P<0.0001). 
In addition, LH levels were significantly lower in Group A compared to Groups B and C (A 
vs B: P=0.0063, A vs C: P=0.0001) (Figure 3). No differences were observed between the 
three groups with respect to biochemical and/or endocrine parameters (Table 2). 
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Discussion 
The association between PCOS and prolactinoma was first described in 1979 in three 
patients presenting with hyperprolactinemia, infertility, a pituitary tumour and bilateral 
wedge resection of the ovaries for PCOS (20). Subsequently, further patients with 
galactorrhea, mildly elevated PRL levels and history of PCOS, were found to have 
prolactinomas (21, 22).  
Since then, the frequency of pituitary adenomas among patients with PCOS and elevated 
PRL levels has been mentioned in only few small studies, overall ranging between 10-69% 
(7, 10, 23, 24). In our study, prolactinomas were identified in 21.7% of patients with PCOS 
and hyperprolactinemia and in 2.46% of all PCOS patients. Of note, the prevalence of ever 
treated hyperprolactinemia among female patients in a large cohort of patients in The 
Netherlands was 93.9/100,000 inhabitants (25).  Thus, the association between PCOS and 
prolactinomas may not be a rare entity. However, there is limited information regarding 
the range of PRL levels in hyperprolactinemic PCOS patients and the prevalence of 
prolactinomas. Mild hyperprolactinemia in the absence of prolactinoma has been 
described in association with PCOS with a variable prevalence, mean PRL values ranging 
from 25.5±2.2 to 40.3±18.4 ng/mL and has been mainly attributed to a relative dopamine 
deficiency and the abnormal hormonal milieu (6-11, 26). Our analysis showed, that PCOS 
patients with prolactinomas had significantly higher PRL levels than hyperprolactinemic 
PCOS patients without adenomas (median PRL 95.4 vs. 49.2 ng/mL, P<0.0001). In addition, 
PRL levels ≥94.0 ng/mL were associated with prolactinomas in all cases. These findings are 
in accordance with previous studies (27, 28), suggesting that when other causes of 
hyperprolactinemia are excluded, PRL levels ≥4xupper normal limit make the possibility of 
functional hyperprolactinemia highly unlikely among PCOS patients and thus warrant 
further imaging investigations.   
 
We tried to establish a cut-off PRL level that could predict the presence of a prolactinoma. 
A cut-off PRL value of 47.5 ng/mL could reliably identify all patients with PCOS and 
coexisting microadenomas albeit with low specificity and PPV of 59.1%, suggesting that a 
considerable number of women with PRL levels >47.5 ng/mL have no pituitary adenoma 
on MRI. Alternatively, PRL levels >85.2 ng/mL were associated with a 100% specificity and 
77% sensitivity for discriminating hyperprolactinemic PCOS patients with prolactinomas 
from those without, as reflected by a high PPV of 100% and an acceptable NPV of 85.7%. 
 
Taken together, it is prudent to suggest that MRI of the pituitary could be justifiable in 
patients with PCOS and elevated PRL  exceeding 85.2 ng/mL.  
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The underlying mechanisms that might associate PCOS with prolactinomas have not yet 
been elucidated. Although the unopposed action of estrogens in PCOS patients could 
stimulate pituitary lactotrophs (20-22), an association between estrogens and the 
formation of prolactinomas or an increase in their volume is less clear (29). In addition, 
elevated PRL levels have been associated with alterations in steroidogenic enzyme 
activities, increased androgen production, insulin resistance, hirsutism and PCO 
morphology (6, 30-33), all of the above being essential components of the PCOS 
phenotype.  
 
PCOS patients with prolactinomas had significantly lower LH levels compared to 
hyperprolactinemic PCOS patients without adenomas and normoprolactinemic PCOS. This 
finding may suggest that patients with PCOS and concomitant prolactinoma may have a 
different gonadotrophin profile from the “classic PCOS”, which is often associated with LH 
excess (20, 22). In addition, women with PCOS and prolactinomas were younger than 
hyperprolactinemic PCOS patients without adenomas. 
 
The main strength of the present study is that we accumulated data from a large number 
of unselected and well-characterized patients with PCOS. To our knowledge this is the first 
study aiming to delineate the clinical and biochemical profile of patients with PCOS and 
concurrent prolactinoma although there are some limitations with regards to the study 
design. Firstly, it is possible that the diagnosis of prolactinoma may have been missed in 
some cases, as 44 out of 60 hyperprolactinemic PCOS subjects were evaluated with 
pituitary MRI. However, the remaining patients presented mainly with mild elevations of 
PRL levels in the absence of symptoms, pointing towards functional hyperprolactinemia. 
Secondly, as this was a retrospective study, we had to deal with missing values in certain 
clinical and biochemical parameters and thus exclude them from our analysis. 
Furthermore, the number of patients with prolactinomas in both groups was relatively 
small. Similarly, larger studies are required in order to establish a cut-off level of serum 
PRL that could more accurately discriminate prolactinomas from functional 
hyperprolactinemia in patients with PCOS. 
 
In conclusion, PRL levels exceeding 85.2 ng/mL in women with PCOS are suggestive of a 
PRL-producing adenoma and warrant pituitary imaging. In addition, pituitary MRI could be 
justifiable in young PCOS patients with milder PRL elevation, low LH levels and 
concomitant symptoms suspicious of a pituitary adenoma. Further studies are needed to 
better elucidate the pathophysiological mechanisms linking PCOS and prolactinoma.  
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Figure Legends 
Figure 1. Schematic representation of patients’ distribution in our study groups.  
PCOS= Polycystic ovary syndrome; CAH= Congenital adrenal hyperplasia; PRL= Prolactin; 
MRI= Magnetic resonance imaging; NFPA=Non-functioning pituitary adenoma; DAs= 
Dopamine agonists  
*=referred for headaches, secondary amenorrhea and galactorrhea  
 **=no reduction of the tumour size on follow-up MRI scans after initiation of treatment 
with DAs 
 
 
 
Figure 2: (Α) Range of serum PRL levels in hyperprolactinemic PCOS patients with and 
without prolactinomas (Β) ROC curve analysis, showing sensitivity and specificity of 
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different serum PRL cut-off values that could distinguish hyperprolactinemic PCOS 
patients with prolactinomas from those without.   
ROC= Receiver operating characteristic; PRL= Prolactin; PCOS: Polycystic ovary syndrome; 
AUC= Area under the curve; IQR= Interquartile range; CI= Confidence interval 
 
Figure 3. LH levels were lower in Group A compared  to Group B and C (A vs B: P=0.0063; A 
vs C: P=0.0001).  
LH= Luteinizing hormone 
 
 
Table 1. Baseline clinical and imaging characterististics in 3 PCOS study groups  
 Group A Group B Group C P values 
Patients (n) 13 18 30  
Age (years) 
Mean ± SD 
 
26±5.4 
 
29.8±4.6 
 
28.7±4.9 
P=0.12 
Group A vs B: P=0.03 
Group A vs C: P=0.13 
Group B vs C: P=0.33 
BMI (Kg/m2)  
Mean ± SD 
 
35.0±8.3 
 
28.8±8.8 
 
30.7±7.8 
P=0.13 
Group A vs B: P=0.15 
Group A vs C: P=0.13 
Group B vs C: P=0.26 
Table 1. Baseline clinical and imaging characterististics in 3 PCOS study groups (cont.) 
Age at menarche 
(years) 
Median (range) 
 
 
12.0 (11-15) 
 
 
12.0 (11-
16) 
 
 
13.5 (11-15) 
P=0.44 
Group A vs B: P=0.8 
Group A vs C: P=0.16 
Group B vs C: P=0.65 
Clinical 
hyperandrogenism 
(n) 
 
7/13 
 
11/12 
 
17/22 
Group A vs B: P=0.07 
Group A vs C: P=0.25 
Group B vs C: P=0.38 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Menstrual 
irregularities (n) 
 
 
12/13 
 
 
15/16 
 
 
26/28 
 
Group A vs B: P=0.8 
Group A vs C: P=0.9 
Group B vs C: P=0.9 
PCO morphology 
(n) 
10/10 11/14 25/27 Group A vs B: P=0.2 
Group A vs C: P=1.0 
Group B vs C: P=0.3 
Table 1. Baseline clinical and imaging characterististics in 3 PCOS study groups (cont.) 
Galactorrhea (n) 5/11 7/11  Group A vs B: P=0.6 
Size of adenoma 
(mm) 
pretreatment* 
median (range) 
 
 
7.7 (4.0-9.0)  
  
P=0.005 
Size of adenoma 
(mm) 
posttreatment** 
median (range) 
 
 
2.5 (0-6)  
PCOS=Polycystic ovary syndrome; Group A= PCOS patients with microprolactinomas; 
Group B= PCOS patients with hyperprolactinemia and normal pituitary magnetic 
resonance imaging (MRI); Group C=PCOS patients with normal PRL levels; SD= standard 
deviation; BMI= Body mass index; vs= versus. 
*Size of pituitary adenoma in Group A before initiation of treatment with dopamine 
agonists. 
** Size of pituitary adenoma in Group A following initiation of treatment with dopamine 
agonists. 
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Table 2.  Metabolic and endocrine parameters in 3 PCOS study groups 
 Group A Group B Group C P values 
Patients (n) 13 18 30  
Hba1c (%) 
median (range) 
 
5.6 (5.0-5.7) 
 
5.6 (5.4-5.9) 
 
5.5 (4.9-7.5) 
P=0.8 
Group A vs B: P=0.7 
Group A vs C: P=0.9 
Group B vs C: P=0.57 
Chol (mg/dL) 
median (range) 
 
239 (131-255) 
 
208 (131-263) 
 
166 (124-278) 
P=0.22 
Group A vs B: P=0.41 
Group A vs C: P=0.11 
Group B vs C: P=0.36 
Table 2.  Metabolic and endocrine parameters in 3 PCOS study groups (cont.) 
TSH (mIU/L) 
median (range) 
 
1.93 (0.87-3.13)  
 
2.88 (0.38-4.18) 
 
1.98 (0.38-5.21) 
P=0.37 
Group A vs B: P=0.63 
Group B vs C: P=0.2 
Group A vs C: P=0.38 
Testosterone 
(ng/dL)  
 
 
 
 
 
 
P=0.74 
Group A vs B: P=0.64 
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median (range) 51.9 (0.58-77.8) 57.6 (17.3-147.0) 53.3 (11.5-172.9) Group A vs C: P=0.43 
Group B vs C: P=0.89 
SHBG (nmol/L) 
median (range) 
 
23.8 (13.3-47.4) 
 
38 (10.7-158.3) 
 
25.9 (1.4-72.1) 
P=0.12 
Group A vs B: P=0.2 
    Group A vs C: P=0.7 
Group B vs C: P=0.06 
Table 2.  Metabolic and endocrine parameters in 3 PCOS study groups (cont.) 
FAI 
median (range) 
 
5.67 (4.43-20.3) 
 
3.21 (1.39-19.54) 
 
7.04 (1.14-59.8) 
P=0.2 
Group A vs B: P=0.2 
Group A vs C: P=0.9 
Group B vs C: P=0.09 
DHEA-S (μg/dL) 
median (range) 
 
365.3 (155.0-405.9) 
 
202.9 (73.8-
383.8) 
 
232.5 (95.9-
483.4) 
P=0.6 
Group A vs B: P=0.43 
Group A vs C: P=0.4 
Group B vs C: P=0.7 
LH (mIU/mL) 
median (range) 
 
3 (0.8-8.3) 
 
7.0 (2.1-20) 
 
9.5 (3.0-53.0) 
P=0.0012 
Group A vs B: P=0.0063 
Group A vs C: P=0.0001 
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Group B vs C: P=0.17 
Table 2.  Metabolic and endocrine parameters in 3 PCOS study groups (cont.) 
FSH (mIU/mL) 
median (range) 
 
5 (2.0-12.7) 
 
5 (2.0-7.0) 
 
5 (3.0-8.0) 
P=0.7 
Group A vs B: P=0.6 
Group A vs C: P=0.4 
Group B vs C: P=0.75 
Estradiol 
(pg/mL) 
median (range) 
 
35.2 (17.2-100.0) 
 
67.3 (16.9-140)  
 
54.0 (20.2-221.8) 
P=0.3 
Group A vs B: P=0.36 
Group A vs C: P=0.19 
Group B vs C: P=0.56 
Table 2.  Metabolic and endocrine parameters in 3 PCOS study groups (cont.) 
PRL (ng/mL) 
median (range) 
 
95.4* (48.3-351.5) 
 
49.2 (25.3-84.3) 
 
9.15 (4.1-23.4) 
P <0.0001  
Group A vs B: P<0.0001  
Group Α vs. C: P<0.0001 
Group B vs C:  P<0.001 
 
PCOS=Polycystic ovary syndrome; Group A= PCOS patients with microprolactinomas; Group B= PCOS patients with hyperprolactinemia and 
normal pituitary magnetic resonance imaging (MRI); Group C=PCOS patients with normal PRL levels; vs= versus; HbA1c= glycated 
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hemoglobin A1c;  TSH= Thyroid-stimulating hormone; SHBG= Sex hormone-binding globulin; FAI= Free-Androgen Index; DHEA-S= 
Dehydroepiandrosterone sulfate; LH= Luteinizing hormone; FSH= Follicle-stimulating hormone; PRL= Prolactin.   
*PRL values in Group A before initiation of treatment with dopamine agonists.   
Reference ranges: HbA1c: values <6.5%; Cholesterol: <193 mg/dL, TSH: 0.27-4.2 mIU/L; Testosterone: <51.9 ng/dL; SHBG: females: 26-110 
nmol/L; FAI: females: <6; DHEA-S: females: 15-19 years (y): 66.4-369.0 μg/dL, 20-24y: 147.6-405.9 μg/dL, 25-34y:  99.6-339.5 μg/dL; 35-44y: 
62.7-339.5 μg/dL; LH: Follicular phase: 2-13 mIU/mL; FSH: Follicular phase: 3-12 mIU/mL; Estradiol: females: Follicular phase: 24.5-195.1 
pg/mL; PRL: <23.6 ng/mL. Conversion factors between conventional and International System of units (SI) were as as follows: Hba1c: % = 
[0.09148 × mmol/mol] + 2.152; Cholesterol: mg/dL = mmol/L÷ 0.0259; Testosterone: ng/dL = nmol/L÷ 0.0347; DHEA-S: μg/dL = μmol/L÷ 
0.0271; FSH: mIU/mL = IU/L ÷ 1; LH: mIU/mL = IU/L ÷ 1; Estradiol: pg/mL = pmol/L ÷ 3.67; Prolactin: ng/mL = nmol/L  ÷ 0.04348.  
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